• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Anticoagulants, Antithrombotics and Fibrinolytics
    35 Drugs classified under this therapeutic system

    All the Therapeutic System Drugs

    Filter by letter: ALL A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
    Boehringer Ingelheim
    not in the basket chart

    Thrombolytic Agent. Alteplase 20 mg/vial, 50 mg/Vial.
    VIAL. (pwdr.+ solvent for sol. for inject./
    infus.): 1 + 1 vial of solvent. Dosage
    must be ajust. individ according to pt.
    med. cond.
    Acute MI: In adults for the lysis of thrombi
    obstruct. coron. arteries, the reduction of
    infarct size, the improve. of ventr. func., the
    reduction of the incidence of congest.
    heart fail., reduct. of mortality assoc. with
    AMI. Tmt. should be initiated as soon as
    possible after the onset of AMI sympt.
    Acute Massive Pulmon. embol. with
    hemodynamic deprivation.: Management
    of acute massive pulmonary embolism
    (PE) in adults: For the lysis of acute pulm.
    emboli, defined as obstruct. of blood flow
    to a lobe or multiple segments of the lung,
    For the lysis of pulmon. emboli
    accompanied by unstable hemodynamics
    e.g. fail.to maintain blood pressure
    without supportive measures.
    The diagnosis should be confirmed by
    objective means, such as pulmon.
    angiography or noninvasive procedures
    such as lung scanning.For fibrinolytic
    treatment of acute ischaemic stroke Tmt.
    must be started as early as possible within
    4.5 hrs. after onset of stroke sympt.and
    after exclusion of intracr. haemorrhage by
    appropriate imaging techniques (e.g.
    cranial CT or other diag. imaging method
    sensitive for the presence of
    haemorrhage). The tmt. effect is timedependent;
    therefore earlier tmt. incr. the
    probability of a favourable outcome.
    C/I: Hypersens. High risk cases of
    haemorrhage such e.g.: Signific. bleed.
    disor. at present or within the past 6
    mnths. Known haemorrhage.diathesis.
    Pts. receiving effective oral anticoag.
    tmt., e.g. warfarin sodium (INR>1.3). Manifest or recent severe or dangerous bleed. Known hist. of or suspected intracran.
    haemorrhage. Suspected subarachnoid
    haemorrhage/condition after subarachnoid haemorrhage from aneurysm. Any history of CNS damage (i.e. neoplasm, aneurysm, intracran./spinal surg.). Recent (less than 10 days) traumatic external heart massage,
    obstetrical delivery, recent puncture of a
    non-compressible blood-vessel (e.g.
    subclavian or jugular vein puncture).
    Severe uncontrol.arterial hypertens.
    Bact. endocarditis, pericarditis. Acute
    pancreatitis. Documented ulcerative GI
    dis. during the last 3 mnths., oesophageal varices, arterial-aneurysm, arterial/venous malformations.
    Neoplasm with incr. bleed.risk. Severe liver dis., includ. hep. fail., cirrhosis, portal hypertension (oesophageal varices) and active hepatitis. Major surg. or signific. trauma in past 3 mnths.
    Addit. contraind. in acute massive pulmonary embolism, MI, acute ischaemic stroke: see lit.
    Acute ischaemic stroke in child. under 16 yrs old.

    partial basket chart

    Antiplatelet Agent. Tirofiban HCl Monohydrate 0.05 mg/ml.
    VIAL FOR INJECT: 1 x 12.5 mg/50 ml
    (0.25 mg/ml).
    INFUS. BAG: 1 x 12.5 mg/250 ml (0.05
    mg/ml). Initial: 0.4 μg/kg/min of
    diluted sol. by I.V. Then 0.1 μg/kg/min.
    See lit.
    In comb. with heparin in unstable
    ang. or non-Q-wave M.I., prevent card.
    ischem. events, acute coronary syndr.
    (incl. medically managed and
    undergoing PTCA or atherectomy). See

    not in the basket chart

    Thrombin Inhibitor. Bivalirudin 250 mg/vial.
    VIALS (pwdr. for I.V. inject.): 1 x 10. I.V.
    bolus: 1.0 mg/kg foll. by 4 hr. infus. at
    rate of 2.5 mg/kg/hr. Aft. complete
    initial 4 hr. infus., addition. I.V. infus.
    may be initiat. at 0.2 mg/kg/hr. for up
    to 20 hrs. if reqd. Use with aspirin (300
    - 325 mg dly). Initiate just prior to
    PTCA. May need to reduce dose and
    anticoag. status monitored in pts. with
    ren. impair.
    Unstable ang. undergoing percutan.
    translum. coron. angioplasty (PTCA). To
    be used with aspirin. See lit. for safety
    and effectiveness.
    C/I: Known hypersens.

    not in the basket chart

    Anticoagulant. Fondaparinux (sodium) 2.5 mg/0.5 ml, 0.75 mg/ 0.6 ml.
    PRE-FILLED SYR. (sol., for inject.): 10 x
    0.5 ml x 2.5 mg, 10 x
    0.6 ml x 0.75 mg. See lit.
    Prevent. VTE in pts. undergoing major
    orthoped. surg. lower limbs. Prevent. VTE in
    pts. undergoing abdom. surg. who are at high risk thromboembol. complicats.
    Prevent. VTE in medical pts. at high risk for
    VTE and immobilised due to acute illness
    such as card. insuffic. and/or acute respirat.
    disords, and/or acute infects. or inflamm.
    dis. Tmt. unstable angina or non-ST segm.
    elevat. myocard. infarct. (UA/NSTEMI) in
    pts. where urgent invas. manage. (PCI) not
    indicat. Tmt. ST segm. elevat. myocard.
    infarct. (STEMI) in pts managed with
    thrombolytics or who are not to receive
    other form reperfus. ther.
    C/I: Hypersens., active clin. bleed., acute
    bact. cardit., severe ren. fail. (creatinine
    clear. <20 ml/min).

    Aspirin 500
    full basket chart
    Aspirin 500

    Salicylate. Acetylsalicylic Acid 500 mg.
    TABS: 20. 1-2 tabs. every 4-8 hrs., max.
    6 tabs dly.
    Pain, fever, antirheumat. tmt., inhibit.
    platelet aggregat.

    Aspirin Cardio
    not in the basket chart
    Aspirin Cardio

    Antiplatelet Agent. Acetylsalicylic Acid 100 mg.
    TABS: 30, 90. 1 tab. dly.
    Prim. prevent. coron. heart dis. in pts at
    incr. risk, second. prevent. thrombot.
    cerebrovasc./cardiovasc. dis.

    Other therapeutic systems under Cardiovascular System